The below update is effective November 17, 2014:
As per the manufacturer’s product monograph for Kadian (sustained released morphine sulphate), this medication indicated for the management of pain severe enough to require daily, continuous, long-term opioid treatment, and:
• that is opioid-responsive; and• for which alternative options are inadequate.Kadian is not indicated as a pain reliever on an as-needed basis.Kadian is a limited use (LU) benefit with the following criteria:• For the treatment of chronic pain OR• For the treatment of opioid dependence where methadone and Suboxone are not available or not appropriate.
Clients receiving coverage of Kadian for opioid dependence treatment will be enrolled in the Prescription Monitoring Program (PMP) to ensure appropriate access to drugs of potential misuse, including certain pain medications, sedatives, and stimulants.
The following updates are effective November 3, 2014:
NIHB regularly reviews the Drug Benefit List (DBL) to look for medications that may no longer play a significant therapeutic role. 282 and 292s are pain medications with acetylsalicylic acid (ASA) and no enteric coating, caffeine, and codeine. 282s (DIN 02234510) and 292s (DIN 02238645) are being removed from the DBL. These products were identified as products which are no longer needed as there are many other options listed for pain.
282s have no claims by clients in 2013 or 2014 to date. There were a small number of claims for 292s; any current clients receiving 292s will be allowed up to one year to transition to another listed pain reliever.
Based on a recommendation from the NIHB Drugs and Therapeutics Advisory Committee (DTAC) which concluded there was limited information available related to the effectiveness of topical antiseptics; the risk of resistance from overuse; and possible toxicities, the following antiseptic agents are delisted from the DBL:
• Triclosan 0.5% (Adasept);• Aluminium diacetate/benzethonium chloride (Buro Sol);• Chlorhexidine/isopropyl alcohol 2% and 4% (Stanhexidine);• Hexachlorophene 3% (Phisohex);• Povidone iodine 10% (Betadine); and• Hydrogen peroxide.
Antiseptic products are exceptions and reviewed on a case by case basis. Alcohol swabs will continue to be covered.
Vitamin D is important for the absorption of calcium from the stomach and for the functioning of calcium in the body. There is insufficient evidence to assess the balance of the benefits and harms of daily low-dose supplementation.
Vitamin D tablets, calcium tablets, and vitamin D and calcium combination tablets are open benefits on the Drug Benefit List (DBL). Only combination products of calcium at 500mg and vitamin D at 400IU, or at higher strengths are listed on the DBL. Combination products with lower strengths are delisted from the DBL.
The below update is effective November 17, 2014:
As per the manufacturer’s product monograph for Kadian (sustained released morphine sulphate), this medication indicated for the management of pain severe enough to require daily, continuous, long-term opioid treatment, and:
• that is opioid-responsive; and• for which alternative options are inadequate.Kadian is not indicated as a pain reliever on an as-needed basis.Kadian is a limited use (LU) benefit with the following criteria:• For the treatment of chronic pain OR• For the treatment of opioid dependence where methadone and Suboxone are not available or not appropriate.
Clients receiving coverage of Kadian for opioid dependence treatment will be enrolled in the Prescription Monitoring Program (PMP) to ensure appropriate access to drugs of potential misuse, including certain pain medications, sedatives, and stimulants.
The following updates are effective November 3, 2014:
NIHB regularly reviews the Drug Benefit List (DBL) to look for medications that may no longer play a significant therapeutic role. 282 and 292s are pain medications with acetylsalicylic acid (ASA) and no enteric coating, caffeine, and codeine. 282s (DIN 02234510) and 292s (DIN 02238645) are being removed from the DBL. These products were identified as products which are no longer needed as there are many other options listed for pain.
282s have no claims by clients in 2013 or 2014 to date. There were a small number of claims for 292s; any current clients receiving 292s will be allowed up to one year to transition to another listed pain reliever.
Based on a recommendation from the NIHB Drugs and Therapeutics Advisory Committee (DTAC) which concluded there was limited information available related to the effectiveness of topical antiseptics; the risk of resistance from overuse; and possible toxicities, the following antiseptic agents are delisted from the DBL:
• Triclosan 0.5% (Adasept);• Aluminium diacetate/benzethonium chloride (Buro Sol);• Chlorhexidine/isopropyl alcohol 2% and 4% (Stanhexidine);• Hexachlorophene 3% (Phisohex);• Povidone iodine 10% (Betadine); and• Hydrogen peroxide.
Antiseptic products are exceptions and reviewed on a case by case basis. Alcohol swabs will continue to be covered.
Vitamin D is important for the absorption of calcium from the stomach and for the functioning of calcium in the body. There is insufficient evidence to assess the balance of the benefits and harms of daily low-dose supplementation.
Vitamin D tablets, calcium tablets, and vitamin D and calcium combination tablets are open benefits on the Drug Benefit List (DBL). Only combination products of calcium at 500mg and vitamin D at 400IU, or at higher strengths are listed on the DBL. Combination products with lower strengths are delisted from the DBL.